Jeetinder Singh Mahal Sells 900 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock

Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Jeetinder Singh Mahal sold 900 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $22.11, for a total transaction of $19,899.00. Following the sale, the chief operating officer now owns 25,009 shares of the company’s stock, valued at $552,948.99. This represents a 3.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Jasper Therapeutics Stock Down 8.9 %

NASDAQ JSPR traded down $2.00 during trading hours on Thursday, hitting $20.47. 155,882 shares of the stock were exchanged, compared to its average volume of 175,119. Jasper Therapeutics, Inc. has a 12-month low of $4.00 and a 12-month high of $31.01. The stock has a 50-day moving average of $20.91 and a 200 day moving average of $20.89. The company has a market cap of $307.07 million, a price-to-earnings ratio of -4.32 and a beta of 2.18.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a report on Thursday, October 24th. Evercore ISI reissued an “outperform” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a report on Monday, August 26th. JMP Securities reaffirmed a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Royal Bank of Canada reduced their price target on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a research report on Wednesday, August 14th. Finally, BMO Capital Markets started coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective on the stock. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $73.38.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of JSPR. BNP Paribas Financial Markets grew its stake in shares of Jasper Therapeutics by 208.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after purchasing an additional 1,698 shares during the period. American Century Companies Inc. grew its position in Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after buying an additional 3,032 shares during the period. Wolff Wiese Magana LLC acquired a new position in Jasper Therapeutics during the third quarter worth about $59,000. Fernwood Investment Management LLC increased its holdings in Jasper Therapeutics by 6.9% in the third quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock valued at $995,000 after buying an additional 3,427 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its position in shares of Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after acquiring an additional 3,873 shares during the period. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.